[PE31] Poster Session 31
Rhinosinusitis

[PE31-18] Baseline characteristics of patients with CRSwNP with asthma and dupilumab efficacy by baseline biomarker level: results from the SINUS-24 and SINUS-52 phase 3 trials

Mikiya Asako¹, Shigeharu Fujieda², Yoshiki Kobayashi¹, Jorge F Maspero³, Joaquim Mullol⁴, Claus Bachert^5,6, Martin Desrosiers⁷, Mei Zhang⁸, Xuezou Mao⁸, Nikhil Amin⁹, Leda P Mannent¹⁰ (1.Department of Otorhinolaryngology, Kansai Medical University, Japan, 2.University of Fukui, Japan, 3.Fundación CIDEA, Argentina, 4.Universitat de Barcelona, Spain, 5.Ghent University, Belgium, 6.Karolinska Institutet, Sweden, 7.CRCHUM, Canada, 8.Sanofi U.S., USA, 9.Regeneron Pharmaceuticals, Inc, USA, 10.Sanofi France, France)